CHRM1 and malignant colon neoplasm: Additionally, our experiments examining the effects of combining an M1R agonist with conventional colon cancer chemotherapeutics (Figure 4E,F) suggest that M1R agonism, alone or in combination with these agents, is a potential therapeutic strategy worthy of further investigation.